Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.
The Echelon-3 study seemed doomed, but it just read out positively for overall survival.
Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
BeiGene has a strong presence at this year’s AACR, which features several notable duels.